X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Optimi will provide Mātai with a quantity of its validated GMP Full Spectrum Natural Psilocybin extract for the treatment of methamphetamine use disorder.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mātai Medical Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 09, 2024
Details:
MDMA-AT (3,4-methylenedioxymethamphetamine) mainly acts as a releaser of serotonin (5-HT) and noradrenaline, and to a lesser extent also of dopamine, which is investigated for the treatment of Posttraumatic Stress Disorder.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA-AT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine,Midomafetamine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
Research shows that up to 80 percent of patients with advanced cancer for Psilocybin are likely to suffer distressing thoughts around death and up to 50 percent of patients with generally incurable conditions are likely to have psychiatric diagnoses.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its previously announced trial in partnership with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Psychedelic Therapy and Research Centre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 13, 2022
Details:
The Company has signed an agreement which will provide SABI Mind’s trained clinical staff with supplies of GMP psilocybin and 3,4-Methylenedioxymethamphetamine (“MDMA”), pending the anticipated approval of its previously announced licensing amendment.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SABI Mind
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
